Potential PsO Breakthrough: Exploring the Role of an Iron-regulating Hormone in the Etiology of Psoriasis

September 26, 2024

Pso Far, PsO Good: Bimekizumab (Bimzelx) Shows Long-term Efficacy in Psoriasis

September 25, 2024

One in Four Psoriasis Patients Show Signs of Psoriatic Arthritis

September 16, 2024

FDA Approves Alembic’s Generic Scalp Psoriasis Treatment

August 28, 2024

Biosimilar Update: EC Approves Stelara Biosimilar

August 26, 2024

Study: Obese Kids May Be More Likely to Develop AD, PsO, or AA

August 21, 2024

Otezla Now Available for Kids With Moderate to Severe Psoriasis

August 20, 2024

Just Published: NPF’s Psoriasis Health Indicator Report

August 16, 2024

Scratching Beneath the Surface: Seven Ways to Elevate Conversations With Patients About Their Skin Conditions

August 9, 2024

FDA Approves Alembic’s Generic Acitretin Capsules for Psoriasis

August 7, 2024

NPF Launches Annual Take ACTION Campaign for Psoriasis Action Month

August 6, 2024

PsO Pipeline Watch: Alumis Initiates Phase 3 Clinical Program Evaluating Its Oral TYK2 Inhibitor in Moderate-to-Severe Plaque PsO

July 29, 2024